Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040822 (tremor)
 18,428 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In order to provide additional data on the in vitro antibacterial activity of cefetamet-pivoxil against respiratory pathogens, we determined the bactericidal kinetics of this antibiotic in comparison to cefixime and ceftibuten against H. influenzae, M. catarrhalis, K. pneumoniae, E. coli, S. pneumoniae and S. pyogenes. time-kill studies were performed by using concentrations equal to a x MIC, and 4 x MIC of the antibiotics tested and different inocula (10(5), 10(7) and 10(9) CFU/ml). The strains were incubated in a shaking incubator at 37 degrees C and 1 ml samples were removed at regular intervals for viable count determination. The antibiotics were eliminated by serial ten-fold dilutions in physiological saline before plating. At 4 x MIC of cefetamet and at 10(5) CFU/ml inoculum the results were 99.9% killing or more of H. influenzae and M. catarrhalis at 4 h, and of E. coli and K. pneumoniae within 4 to 6 h, and of E. coli and K. pneumoniae within 4 to 6 h. At the same concentration of MIC and with the same inoculum a 99.9% reduction was achieved against S. pneumoniae within 4 h and against S. pyogenes within 2 h with no regrowth at 24 h in both cases. Similar results were obtained using 10(7) and 10(9) CFU/ml inocula. Cefetamet had efficient killing activity even at lower concentrations. Bactericidal kinetics of cefetamet favorably compare with those of cefixime and ceftibuten. The efficient bactericidal activity of cefetamet-pivoxil indicates a clinical role for this new oral cephalosporin in the treatment of respiratory tract infections.
 ...
PMID:Third generation oral cephalosporins: comparative in vitro kinetics. 861 12

This study tested the protective activity of antibodies to the LPS core of Haemophilus influenzae (Borrelli et al., Infect. Immun. 1995;63: 3683-92) in a hematogenous meningitis model. Meningitis was established by intraperitoneal inoculation of infant rats with H. influenzae type b (Hib). The severity of infection was determined by daily assessment of mortality, symptoms of disease and weight changes. Mortality occurred rapidly after infection with 10(5)cfu/rat and most animals died within 24 h. At a lower infection dose (10(4)cfu/rat) the rats survived, but developed symptoms of disease such as tremor, hypothermia, lethargy and anorexia within 12-72 h post challenge. Surviving animals showed decreased weight gain. Bacteremia was detected by daily blood-cultures in 10/10 rats and cleared 6 days after inoculation. The monoclonal anti-LPS antibody MAHI 3 was used in passive protection studies. MAHI 3 increased the survival in the high inoculum group (10(5)cfu/rat) from 10-17% in control animals to 60-90%. At the lower inoculum concentration (10(4)cfu/rat) MAHI 3 treatment reduced the symptoms and blood counts. Intraperitoneal injection of MAHI 3 was more effective than intranasal injection as shown by the effect on bacteremia. We conclude that anti-LPS antibodies can protect against mortality caused by hematogenous Hib infections in infant rats.
 ...
PMID:Monoclonal anti-LPS inner core antibodies protect against experimental hematogenous Haemophilus influenzae type b meningitis. 1062 58